Register For Our Mailing List

Register to receive our free weekly newsletter including editorials.

Home / Sponsors / Chi-X Australia

Chi-X Australia

Chi-X Australia (CXA) is the innovative securities and derivatives exchange committed to transforming, improving and growing Australian investment markets by providing brokers and investors with the most efficient and cost-effective access to local and global investment opportunities. This focus has seen the alternative trading platform for Australian listed securities grow strongly from its launch in October 2011 to have achieved over 20% market share and trade over $1 billion a day in cash equities.

Today, the ASIC regulated market operator provides investors with a combination of world class technology, innovation and cost-efficient product offerings that has attracted close to 50 market participants and thousands of investors.

The Chi-X investment product platform offers trading across a range of unique products including Transferable Custody Receipts, or TraCRs, which give Australian investors access to the benefits of owning US shares in companies behind some of the world’s biggest brands. TraCRs are exclusively quoted and traded on Chi-X.

Chi-X also offers over 900 uniquely quoted warrants across a range of asset classes including equities from Australia’s largest companies, indices, currencies, commodities and fixed income.

The Chi-X Funds market includes both Exchange Traded Funds (ETFs) and Quoted Managed Funds (QMFs). ETFs are passively managed funds that track a particular index whereas QMFs are funds that are rules-based, actively managed or hold only single assets.

The Chi-X Australia 200 Index (CXA 200 Index) is a free-float capitalisation weighted index that captures approximately 80% (by total market capitalisation) of the Australian equity market. The index measures the performance of the largest 200 companies and is calculated using transacted prices from the CXA market. All index values are real-time or end-of-day.

For more information visit www.chi-x.com.au

Connect with Chi-X

        

Video

To find out more about TraCRs visit tracrs.com.au

 

Latest sponsor articles

Finding companies in four themes COVID-19 has accelerated

A new sponsor, Chi-X, shows how it follows long-term trends reinforced by COVID-19 to select US-listed companies accessible on local exchanges, often in sectors not served by Australian companies.

Baseline outlook for economic recovery is too optimistic

We cannot throw our hands up in the air and say 'this time around, it's simply too hard'. Having no macro view is unhelpful, but many of the baseline scenarios are overly optimistic, says the former CEO of Westpac and now Chairman of Chi-X Australia.

Most viewed in recent weeks

After 30 years of investing, I prefer to skip this party

Eventually, prices become so extreme they bear no relationship to reality, and a bubble forms. I believe we are there today, not for all stocks but for many in the technology space.

Australian house prices: Part 2, the bigger picture

There is good reason to believe the negatives will continue to outweigh the positives over the next 12 to 18 months. There is more concern about house prices than the short-term indicators suggest.

How to handle the riskiest company results in history

It is better to miss a results bounce and buy after the company has delivered than it is to step on a landmine. With such uncertainty, avoid FOMO by following these result season investing tips.

Australian house prices: Part 1, how worried should we be?

Three key indicators are useful for predicting the short-term outlook for house prices, although tighter lockdowns make the outlook gloomier. There is enough doubt to create cause for concern.

Welcome to Firstlinks Edition 367

There is a similarity between the current health crisis and economic crises of the past. For COVID-19, record amounts of biotech funding from government agencies and private companies are looking for a vaccine. Likewise, central banks once struggled treating recessions but the 'vaccine' now is record amounts of financial stimulus to ensure liquidity. While the world awaits a COVID treatment, markets are purring along, at least until side effects hit.

  • 22 July 2020

Welcome to Firstlinks Edition 369

Imagine you had perfect foresight about COVID-19 at the start of the year. You correctly foresaw that the global pandemic would kill over 700,000 among 20 million infections by August. In Australia, borders would close, cities would be locked down, most mortgagors would be on income support and companies would be allowed to trade while insolvent. You then had to guess how much the stock market would fall. Would you say about 10%?

  • 6 August 2020

Sponsors

Alliances

© 2020 Morningstar, Inc. All rights reserved.

Disclaimer
The data, research and opinions provided here are for information purposes; are not an offer to buy or sell a security; and are not warranted to be correct, complete or accurate. Morningstar, its affiliates, and third party content providers are not responsible for any investment decisions, damages or losses resulting from, or related to, the data and analyses or their use.
Any general advice or class service prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Ltd, subsidiaries of Morningstar, Inc, has been prepared by without reference to your objectives, financial situation or needs. Refer to our Financial Services Guide (FSG) for more information. You should consider the advice in light of these matters and if applicable, the relevant Product Disclosure Statement before making any decision to invest. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your situation, contact a professional financial adviser. Articles are current as at date of publication.
This website contains information and opinions provided by third parties. Inclusion of this information does not necessarily represent Morningstar’s positions, strategies or opinions and should not be considered an endorsement by Morningstar.